NCT05625737 2024-09-19
Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
Clinical Trials
64 trialsNCT06227325 2024-01-26
Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression
Henan Cancer Hospital
Phase 2 Unknown
NCT06161909 2023-12-08
Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection
Fujian Medical University Union Hospital
Phase 3 Unknown
NCT06120127 2023-11-07
IMPROVE
Fudan University
Phase 2 Unknown
NCT05250843 2023-10-13
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2/3 Unknown
NCT05307198 2023-10-10
RAIC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT05010434 2023-09-21
Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT06046963 2023-09-21
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT06029829 2023-09-08
The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.
China Three Gorges University, Yichang, China
Phase 2 Unknown
NCT05795296 2023-08-30
Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer
RenJi Hospital
Phase 2 Unknown
NCT05971199 2023-08-02
Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04724239 2023-08-01
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT04267549 2023-07-06
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05928897 2023-07-05
Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab
Xiangya Hospital of Central South University
Phase 2 Unknown
NCT05913661 2023-06-22
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05653180 2023-04-03
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Unknown
NCT05781074 2023-03-24
CASTLE-08
Fudan University
Phase 2 Unknown
NCT05616390 2023-03-21
Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04194359 2023-03-17
Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT05720533 2023-02-09
Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05029973 2023-02-08
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05225116 2023-02-08
Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Beijing Tsinghua Chang Gung Hospital
Phase 1 Unknown
NCT04984980 2023-01-26
Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer
Fudan University
Phase 2 Unknown
NCT05627414 2022-11-25
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05627427 2022-11-25
Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05617430 2022-11-15
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT04718909 2022-11-10
REGSIN
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT05594381 2022-10-26
A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04720716 2022-09-19
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Unknown
NCT05530785 2022-09-07
Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT
Hunan Province Tumor Hospital
Phase NA Unknown
NCT05524155 2022-09-01
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05279677 2022-08-23
FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage
ChineseAMS
Phase 2 Unknown
NCT05461235 2022-07-18
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
China Medical University, China
Phase 2 Unknown
NCT05438108 2022-06-29
SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC
Huazhong University of Science and Technology
Phase 2 Unknown
NCT04174781 2022-06-09
Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC
Zhejiang University
Phase 2 Unknown
NCT05363722 2022-05-06
A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 1 Unknown
NCT05339581 2022-04-27
iPLENTY-pvtt
RenJi Hospital
Phase NA Unknown
NCT05216237 2022-04-11
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer
Affiliated Hospital of Qinghai University
Phase 2 Unknown
NCT05322187 2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3 Unknown
NCT05218148 2022-04-06
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma
ChineseAMS
Phase 2 Unknown
NCT05292417 2022-03-31
Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
The First Affiliated Hospital of Xiamen University
Phase 2 Unknown
NCT05251662 2022-02-23
Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05233358 2022-02-10
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
Phase NA Unknown
NCT05207735 2022-01-26
SCRCA
Henan Cancer Hospital
Phase 2 Unknown
NCT05174325 2021-12-30
Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05166772 2021-12-22
Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04796025 2021-09-28
T-Double
Sun Yat-sen University
Phase 2 Unknown
NCT05002686 2021-08-24
Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis
Ruijin Hospital
Phase 2/3 Unknown
NCT04535024 2021-05-11
The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer
Fudan University
Phase 2 Unknown
NCT04843943 2021-04-14
Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC
Fudan University
Phase 1/2 Unknown